Success Metrics

Clinical Success Rate
100.0%

Based on 19 completed trials

Completion Rate
100%(19/19)
Active Trials
0(0%)
Results Posted
79%(15 trials)

Phase Distribution

Ph phase_3
13
68%
Ph phase_4
4
21%

Phase Distribution

0

Early Stage

0

Mid Stage

17

Late Stage

Phase Distribution17 total trials
Phase 3Large-scale testing
13(76.5%)
Phase 4Post-market surveillance
4(23.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

19 of 19 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(19)

Detailed Status

Completed19

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 313 (76.5%)
Phase 44 (23.5%)

Trials by Status

completed19100%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT03022097Phase 3

Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients

Completed
NCT03290287

Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints

Completed
NCT01966107Phase 4

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

Completed
NCT03333018

A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)

Completed
NCT02375724Phase 4

BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH

Completed
NCT01572792Phase 3

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT01437397Phase 3

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT01462942Phase 3

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Completed
NCT01045161Phase 3

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

Completed
NCT00970268Phase 3

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Completed
NCT00891462Phase 3

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

Completed
NCT00363896Phase 3

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00500318Phase 3

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT01471171Phase 3

Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00358436Phase 3

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Completed
NCT01462929Phase 3

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00435760Phase 3

Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Completed
NCT02153489Phase 4

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02181023Phase 4

Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19